Pharmacy Medical News about Cyclophosphamide

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

High-Dose Cyclophosphamide in the Treatment of Multiple Sclerosis
CNS Neuroscience & Therapeutics, 07/07/09

Schwartzman RJ et al. - High dose cyclophosphamide (HDC) has been successfully used for the treatment of a variety of autoimmune diseases. HDC was well tolerated, demonstrated a good safety profile and had minimal adverse effects. These results along with previous reports suggest that early use of HDC therapy in RRMS is promising.

<< Previous
Spinal Cord Stimulation : Advanced Pain Therapy For Failed Back...

Next >>
Parental attitudes toward new dosage forms of desloratadine in an...

Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer
Journal of Clinical Oncology, 11/13/09 Relevance Score: 87%

High-dose cyclophosphamide treatment for refractory severe aplastic anemia in children
Pediatric Blood & Cancer, 10/22/09 Relevance Score: 87%

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: childrens oncology group study d9803
Journal of Clinical Oncology, 10/08/09 Relevance Score: 87%

Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
Journal of Clinical Oncology, 10/30/09 Relevance Score: 85%

A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer
Annals of Oncology, 10/26/09 Relevance Score: 84%